Insights to inform treatment that can improve outcomes
For doctors treating patients with advanced cancer, the Guardant360® portfolio of tests provides a complete genomic view at every step of the treatment journey, delivering insights to quickly match patients to the right targeted treatment based on their genomic profile, and also monitor response to that treatment.
The first FDA-approved blood test for complete genomic testing
Our Guardant360® CDx test is FDA-approved for complete genomic testing across all solid cancers, providing doctors guideline-complete genomic results in 7 days from a simple blood draw to inform treatment decisions. A blood test does not require tissue testing, enabling more patients to benefit from the growing number of FDA-approved targeted therapies. Starting with the Guardant360 CDx test for complete genomic profiling identifies more patients with actionable biomarkers more quickly than starting with tissue biopsy.1-3 The test covers all genes recommended by the National Comprehensive Cancer Network, including the 55 most relevant to clinical care. The test is approved as a companion diagnostic to identify patients with non-small cell lung cancer who may benefit from treatment with TAGRISSO® (osimertinib), RYBREVANT® (amivantamab-vmjw), ENHERTU® (fam-trastuzumab deruxtecan-nxki) or LUMAKRAS™ (sotorasib). It is also FDA approved to identify advanced breast cancer patients with ESR1 mutations who may benefit from treatment with ORSERDU™ (elacestrant).
If you are a healthcare provider in the United States looking for more information about Guardant360 CDx, please visit this product website. If you are located in Europe & Latin America, please visit this website. If you are in Canada, please visit this website. If you are a healthcare provider in Asia, Middle East, or Africa, please visit this website.